The treatment of acute myeloid leukaemia (AML) is rapidly changing, and treatment decisions are more complex, with increasing therapeutic options available for those ‘unfit’ for intensive cytotoxic therapy. With the median age of 69 years at diagnosis, frailty is expected to be highly prevalent in patients with AML. An individualised approach is required, accounting for disease biology, chronological age, functional status, social factors, patient-directed goals of care and co-morbidities. This Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement aims to highlight the importance of performing geriatric and frailty assessments (FAs) in older patients diagnosed with AML and provide practical recommendations on integrating FAs into routine clinical practice within the Australian and New Zealand context. We recommend FAs be widely implemented and tailored to the resources of individual centres to provide an objective measure of fitness of older patients with AML to assist therapeutic decisions at diagnosis as well as at serial timepoints throughout the disease course. Deficits in domains identified by FAs can specifically be targeted through supportive care interventions aiming to improve tolerance of therapy. FAs should be incorporated into clinical trials and be prioritised for funding and resources.

急性髓系白血病（AML）的治疗格局正快速演变，治疗决策日趋复杂—尤其对于不适合强化疗（"unfit"）的患者，可选方案日益增多。鉴于AML确诊中位年龄达69岁，衰弱状态在患者中普遍存在。诊疗需采取个体化策略，综合考量疾病生物学特征、实际年龄、功能状态、社会因素、患者自主医疗意愿及共病情况。本澳大利亚白血病与淋巴瘤研究协作组（ALLG）共识声明旨在：强调老年AML患者实施衰弱评估（FA）与老年综合评估的重要性，并结合澳大利亚与新西兰的临床实践背景，为将 FA 整合至常规诊疗流程提供实用性建议。我们建议广泛推行 FA，并根据各中心资源条件进行个性化调整，以客观评估老年 AML 患者的治疗适应性，从而在诊断时及疾病全程的系列时间点辅助治疗决策。通过 FA 识别的功能领域缺陷，可针对性地采用支持治疗干预措施，以改善患者对治疗的耐受性。此外，FA 应纳入临床试验，并优先获得资金与资源支持。